| Theme | Interferon Therapy for Viral Hepatitis : an Update Reference | |
|---|---|---|
| Title | Nucleoside Analog Therapy for Chronic Hepatitis B Patients | |
| Publish Date | 2007/04 | |
| Author | Tatsuya Ide | Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine |
| Author | Michio Sata | Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine |
| [ Summary ] | The indications for nucleoside analog treatment for chronic hepatitis B are generally thought to be those patients over 35 years of age, having the fluctuations in ALT levels, over 105 copies / ml of HBV DNA and at more than a moderate stage of fibrosis. In naive cases, entecavir is recommended. In patients receiving ongoing lamivudine treatments and those patients having lamivudine resistant HBV and who have progressed to breakthrough hepatitis, a combination therapy of lamivudine and adefovir is recommended. In lamivudine treated patients who are not lamivudine resistant, it is controversial whether to continue lamivudine or to switch to entecavir. | |